Parkville Pharmaceuticals Egypt Limited

Based in Egypt, Parkville Pharmaceuticals Egypt Limited specializes in the formulation and distribution of cosmeceutical and aesthetic products aimed at enhancing skin health and beauty. Parkville Pharmaceuticals Egypt Limited is dedicated to the development of innovative skincare solutions. Founded in 2008 Sherif Bassiouny and Mahmoud Farrag and headquartered in Cairo, Egypt, the company has engaged in 2 notable deals, with the most recent occurring on January 25, 2026. Parkville Pharmaceuticals specializes in cosmeceutical and aesthetic products, focusing on skin health and beauty solutions crafted with consumer needs in mind.

Their product range includes a variety of skincare treatments that leverage advanced technologies and high-quality ingredients, aiming to deliver visible results while adhering to stringent safety and efficacy standards. The company’s offerings cater to individual consumers and retail partners, serving a diverse client base across the Middle East and North Africa. Parkville's commitment to excellence is reflected in its team of skilled researchers, scientists, and beauty specialists, who continuously innovate to develop products tailored to the evolving needs of their customers. Parkville Pharmaceuticals employs a business model that combines B2B and direct-to-consumer sales, facilitating transactions through partnerships with retailers and wholesalers.

The company generates revenue by supplying a range of skincare products, which includes flagship offerings recognized for their efficacy in the cosmeceutical sector. Sales are structured around bulk orders for retailers and targeted campaigns for direct consumers, allowing for flexibility in pricing and product availability. Active participation in industry conferences and exhibitions enhances brand visibility, contributing to revenue growth and market penetration. In January 2026, Adenia Partners agreed to acquire a majority stake in Parkville Pharmaceuticals Egypt Limited from Admaius Capital Partners, although financial terms were not disclosed.

This acquisition will help Parkville Pharmaceuticals Egypt Limited to further accelerate its next phase of growth. The company is expected to introduce new products designed to meet the evolving demands of the skincare market, with specific details on upcoming launches yet to be announced. Plans for geographical expansion are also underway, targeting new markets in the Middle East and North Africa by the end of 2026.